Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | KLKB1 | P03952 | 12/20 | 0.59 |
| ▸ | KLK1 | P06870 | 8/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9752787 | 0.90 | POLB (0.63) | POLBNPSR1KLKB1KLK1KDM4E | |
| SCHEMBL16881558 | 0.85 | POLB (0.54) | POLBNPSR1KLKB1KLK1KDM4E | |
| SCHEMBL1768170 | 0.84 | POLB (0.61) | POLBNPSR1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL1240350 | 0.83 | MAPT (0.56) | POLBNPSR1KLKB1KDM4EALDH1A1 | |
| SCHEMBL4591947 | 0.83 | POLB (0.61) | POLBNPSR1KLKB1KLK1KDM4E | |
| SCHEMBL16881026 | 0.83 | POLB (0.56) | POLBNPSR1KLKB1KLK1KDM4E | |
| Hydrochloric Acid SCHEMBL9523272 | 0.82 | KDM4E (0.60) | POLBNPSR1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL16891528 | 0.81 | MAPT (0.61) | POLBNPSR1KLKB1KDM4EALDH1A1 | |
| SCHEMBL16246832 | 0.81 | POLB (0.54) | POLBNPSR1KLKB1KLK1KDM4E | |
| SCHEMBL15873869 | 0.81 | POLB (0.54) | POLBNPSR1KLKB1KLK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308125-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240190892-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | US | disclosed |
| CN-117396469-A | Inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190892-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | POLB 4437/4885NPSR1 2119/4885KLKB1 1/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | POLB 4699/4885NPSR1 1182/4885KLKB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.